The ethics and economics of human longevity | Raiany Romanni-Klein | TEDxBoston

Quick Overview

The talk argues that the perceived ethical and economic barriers to radical life extension are fundamentally flawed, comparing the current resistance to funding aging research to past societal opposition against women's suffrage and the funding of antibiotics, concluding that extending healthy human lifespan is both ethically justifiable and economically beneficial, potentially yielding trillions in long-term returns.

Key Points: Historically, extraordinary advancements like the doubling of lifespan in C. elegans worms by altering just two genes (daf-2 and rsks-1) have been met with societal resistance, mirroring opposition to women's suffrage and antibiotic funding in the 1920s. In the US, Social & Medical Care for adults 65+ is projected to cost $3 Trillion by 2029, vastly outweighing the $1 Trillion projected for the military, highlighting the current economic reality of aging. Age-related diseases (like cardiovascular disease, cancer, and neurodegenerative diseases) account for 75% (45 million deaths) of global mortality in 2024, far exceeding infectious diseases (12%) and accidents/violence (8%). Economists estimate that curing cancer alone could add $80 Trillion in economic value to the US economy over the long run, and slowing aging by just one year could yield about $3 Trillion annually in US GDP gain. The current NIH funding structure prioritizes treating late-stage diseases ($18B in 'Other' category) over fundamental research into the biology of aging ($500M), despite aging being the primary risk factor for most major diseases. If aging were treated akin to a disease, the potential economic returns are massive, with a five-year extension of biological aging yielding $101.9 Trillion in long-term returns based on one model. The speaker suggests that maintaining the status quo (slowly dying in poor health) is both ethically and economically irresponsible, advocating for prioritizing R&D in aging biology.

Context: Raiany Romanni-Klein, CEO of the Institute for Life and Technology and founder of the Amaranth Foundation, presents at TEDxBoston, framing the pursuit of radical life extension not just as a scientific challenge but as an urgent ethical and economic imperative. She contrasts the massive societal costs associated with treating age-related diseases today with the potential economic benefits of slowing the aging process itself, drawing historical parallels to past societal resistance against accepted progress.